{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-025995","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2022-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.119481+00:00","generated_at":"2026-06-21T10:21:37.380083+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Nkarta announces Dec 5 call to review updated NKX019 clinical data; no data in filing","bullets":["Conference call scheduled for December 5, 2022 at 8:00 a.m. ET to review updated clinical data from NKX019.","NKX019 is a CD19-directed CAR NK cell therapy for cancer; no specific data provided in the press release.","Slides will be posted on Nkarta's website; a replay will be available for 4 weeks."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-025995","json":"https://secwatch.observer/filing/0000950170-22-025995.json","markdown":"https://secwatch.observer/filing/0000950170-22-025995.md","text":"https://secwatch.observer/filing/0000950170-22-025995.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022025995/0000950170-22-025995-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022025995/nktx-20221202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T10:21:37.380083+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}